Study of PRT12396 for JAK2-positive blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental drug, PRT12396, for people with certain blood cancers (polycythemia vera or myelofibrosis) that have a specific JAK2 mutation. It aims to see if the drug is safe and starts to work against the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have either polycythemia vera (PV) or myelofibrosis (MF) diagnosed by specific World Health Organization criteria.
- You must have a specific genetic change called JAK2 V617 mutation in your blood cells.
- You should be generally active and able to care for yourself (ECOG score 0-2).
- You must have adequate kidney, liver, and bone marrow function.
- You cannot have had prior treatment for PV or MF (like other drugs, stem cell transplant, or spleen removal) that would conflict with this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ZE74-0282 in patients with a specific type of blood cancer caused by a JAK2 V617F mutation. The drug is designed to target and slow the growth of these cancer cells.
This trial tests an experimental drug called AJ1-11095 for people with myelofibrosis who no longer respond to a type of JAK2 inhibitor. It aims to see if the drug can shrink the spleen, improve symptoms, and be safe.
This trial tests if pacritinib, a JAK inhibitor, can help people with myelofibrosis who also have low platelet counts. It may be an option for those who haven't had JAK inhibitor therapy before or who didn't respond to a previous one.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.